Immunotherapy to shrink advanced liver cancer before transplant
Part of Cancer, Digestive system clinical trials.
This trial tests an immunotherapy “downstaging” plan to shrink hepatocellular carcinoma (a type of liver cancer) so it may become treatable with a liver transplant. You may be eligible if your cancer is beyond transplant limits but is still only in the liver, and you meet specific liver function and health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and follow the visit and lab schedule
- Your diagnosis is confirmed as hepatocellular carcinoma (HCC) by scan or biopsy
- Your HCC is beyond the usual transplant size limits, but has no spread to lymph nodes or other organs
- Your liver function is fairly preserved (Child-Pugh 7 or less) with no serious confusion from liver disease
- You have not had any immunotherapy in the 6 months before starting this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests giving atezolizumab plus bevacizumab before liver transplant in people with hepatocellular carcinoma (HCC) that is too advanced to be listed within the “Milan criteria,” but still transplant-eligible. The goal is to control the cancer outside the transplant period and improve transplant outcomes.
Hear when a new Liver Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.